Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study
Objective: The effect of bevacizumab on platinum sensitivity in recurrent ovarian cancer remains poorly understood. This study examined the association between platinum-free interval (PFI) and sensitivity to subsequent platinum-containing chemotherapy in patients with first relapsed ovarian cancer a...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Gynecologic Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578925000657 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850113469289857024 |
|---|---|
| author | Tamaki Tanaka Kazuhiro Takehara Tomoka Usami Masako Ishikawa Eiji Kondo Masahiro Kagabu Kei Hirabayashi Noriomi Matsumura Shinya Sato Masato Nishimura Atsushi Arakawa Keiichiro Nakamura Yosuke Konno Satoe Fujiwara Kotaro Sueoka Hiroko Nakamura Iemasa Koh Kimihiko Ito Atsushi Hongo |
| author_facet | Tamaki Tanaka Kazuhiro Takehara Tomoka Usami Masako Ishikawa Eiji Kondo Masahiro Kagabu Kei Hirabayashi Noriomi Matsumura Shinya Sato Masato Nishimura Atsushi Arakawa Keiichiro Nakamura Yosuke Konno Satoe Fujiwara Kotaro Sueoka Hiroko Nakamura Iemasa Koh Kimihiko Ito Atsushi Hongo |
| author_sort | Tamaki Tanaka |
| collection | DOAJ |
| description | Objective: The effect of bevacizumab on platinum sensitivity in recurrent ovarian cancer remains poorly understood. This study examined the association between platinum-free interval (PFI) and sensitivity to subsequent platinum-containing chemotherapy in patients with first relapsed ovarian cancer after bevacizumab chemotherapy. Methods: We retrospectively analyzed patients who received platinum-based chemotherapy for platinum-sensitive recurrence between November 2013, and December 2019, and who were initially treated by platinum-based chemotherapy with concurrent and maintenance bevacizumab. The primary endpoint was response rate to subsequent chemotherapy after various periods of PFI. The relevance between response rate and PFI was assessed for each PFI of 6–12, 12–24 and ≧24 months using Cochran-Armitage test. The secondary endpoint was progression-free survival (PFS) defined as time from chemotherapy for first recurrence to subsequent progression and response rate to subsequent chemotherapy for each treatment-free interval since last administration of bevacizumab (Bev-TFI). Results: A total of 77 patients were eligible. The median PFI until first recurrence was 12 months (range: 6–43). The response rates of subsequent chemotherapy for patients with PFI of 6–12, ≥12-24, and 24 months were 42 %, 65 %, and 80 %, showing a linear trend (p < 0.05). Median PFS among the three groups was 8 (95 %CI: 6.7–9.2), 11 (95 %CI: 8.4–13.5) and 13 months (95 % CI: 5.4–20.5) (p = 0.107, log-rank test), respectively. By contrast, no linear trend was observed between Bev-TFI and response rate (p = 0.225) Conclusion: In patients with first relapse of primary ovarian cancer and bevacizumab beyond progression, the prolonged PFS effect of bevacizumab does not seem to affect sensitivity to subsequent platinum-based chemotherapy. |
| format | Article |
| id | doaj-art-0644e7fc701740b29de57089ca525930 |
| institution | OA Journals |
| issn | 2352-5789 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj-art-0644e7fc701740b29de57089ca5259302025-08-20T02:37:09ZengElsevierGynecologic Oncology Reports2352-57892025-06-015910174010.1016/j.gore.2025.101740Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup studyTamaki Tanaka0Kazuhiro Takehara1Tomoka Usami2Masako Ishikawa3Eiji Kondo4Masahiro Kagabu5Kei Hirabayashi6Noriomi Matsumura7Shinya Sato8Masato Nishimura9Atsushi Arakawa10Keiichiro Nakamura11Yosuke Konno12Satoe Fujiwara13Kotaro Sueoka14Hiroko Nakamura15Iemasa Koh16Kimihiko Ito17Atsushi Hongo18Department of Perinatology and Gynecology, Kagawa University Graduate School of Medicine, Kagawa, Japan; Corresponding author at: Department of Perinatology and Gynecology, Kagawa University Graduate School of Medicine, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.Department of Gynecologic Oncology, NHO Shikoku Cancer Center, Ehime, JapanDepartment of Obstetrics and Gynecology, Ehime University Graduate School of Medicine, Ehime, JapanDepartment of Obstetrics and Gynecology, Shimane University Faculty of Medicine, Shimane, JapanDepartment of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Mie, JapanDepartment of Obstetrics and Gynecology, Iwate Medical University, Iwate, JapanDepartment of Obstetrics and Gynecology, JCHO Tokuyama Central Hospital, Yamaguchi, JapanDepartment of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, JapanDepartment of Obstetrics and Gynecology, Faculty of Medicine Tottori University, Tottori, JapanDepartment of Obstetrics and Gynecology, Tokushima Prefectural Central Hospital, Tokushima, JapanDepartment of Obstetrics and Gynecology, Nagoya City University West Medical Center, Aichi, JapanDepartment of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JapanDepartment of Obstetrics and Gynecology, Hokkaido University Hospital, Hokkaido, JapanDepartment of Obstetrics and Gynecology, Osaka Medical and Pharmaceutical University, Osaka, JapanDepartment of Obstetrics and Gynecology, Yamaguchi University Graduate School of Medicine, Yamaguchi, JapanDepartment of Obstetrics and Gynecology, NHO Kure Medical Center and Chugoku Cancer Center, Hiroshima, JapanDepartment of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, JapanDepartment of Obstetrics and Gynecology, Kansai Rosai Hospital, Hyogo, JapanDepartment of Obstetrics and Gynecology, Kawasaki Medical School, Okayama, JapanObjective: The effect of bevacizumab on platinum sensitivity in recurrent ovarian cancer remains poorly understood. This study examined the association between platinum-free interval (PFI) and sensitivity to subsequent platinum-containing chemotherapy in patients with first relapsed ovarian cancer after bevacizumab chemotherapy. Methods: We retrospectively analyzed patients who received platinum-based chemotherapy for platinum-sensitive recurrence between November 2013, and December 2019, and who were initially treated by platinum-based chemotherapy with concurrent and maintenance bevacizumab. The primary endpoint was response rate to subsequent chemotherapy after various periods of PFI. The relevance between response rate and PFI was assessed for each PFI of 6–12, 12–24 and ≧24 months using Cochran-Armitage test. The secondary endpoint was progression-free survival (PFS) defined as time from chemotherapy for first recurrence to subsequent progression and response rate to subsequent chemotherapy for each treatment-free interval since last administration of bevacizumab (Bev-TFI). Results: A total of 77 patients were eligible. The median PFI until first recurrence was 12 months (range: 6–43). The response rates of subsequent chemotherapy for patients with PFI of 6–12, ≥12-24, and 24 months were 42 %, 65 %, and 80 %, showing a linear trend (p < 0.05). Median PFS among the three groups was 8 (95 %CI: 6.7–9.2), 11 (95 %CI: 8.4–13.5) and 13 months (95 % CI: 5.4–20.5) (p = 0.107, log-rank test), respectively. By contrast, no linear trend was observed between Bev-TFI and response rate (p = 0.225) Conclusion: In patients with first relapse of primary ovarian cancer and bevacizumab beyond progression, the prolonged PFS effect of bevacizumab does not seem to affect sensitivity to subsequent platinum-based chemotherapy.http://www.sciencedirect.com/science/article/pii/S2352578925000657Ovarian cancerBevacizumabChemotherapyPlatinum-sensitive relapsePlatinum-free interval |
| spellingShingle | Tamaki Tanaka Kazuhiro Takehara Tomoka Usami Masako Ishikawa Eiji Kondo Masahiro Kagabu Kei Hirabayashi Noriomi Matsumura Shinya Sato Masato Nishimura Atsushi Arakawa Keiichiro Nakamura Yosuke Konno Satoe Fujiwara Kotaro Sueoka Hiroko Nakamura Iemasa Koh Kimihiko Ito Atsushi Hongo Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study Gynecologic Oncology Reports Ovarian cancer Bevacizumab Chemotherapy Platinum-sensitive relapse Platinum-free interval |
| title | Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study |
| title_full | Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study |
| title_fullStr | Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study |
| title_full_unstemmed | Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study |
| title_short | Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study |
| title_sort | evaluation of platinum free interval and chemotherapeutic effect of subsequent platinum containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab sgsg018 intergroup study |
| topic | Ovarian cancer Bevacizumab Chemotherapy Platinum-sensitive relapse Platinum-free interval |
| url | http://www.sciencedirect.com/science/article/pii/S2352578925000657 |
| work_keys_str_mv | AT tamakitanaka evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT kazuhirotakehara evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT tomokausami evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT masakoishikawa evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT eijikondo evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT masahirokagabu evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT keihirabayashi evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT noriomimatsumura evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT shinyasato evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT masatonishimura evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT atsushiarakawa evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT keiichironakamura evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT yosukekonno evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT satoefujiwara evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT kotarosueoka evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT hirokonakamura evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT iemasakoh evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT kimihikoito evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy AT atsushihongo evaluationofplatinumfreeintervalandchemotherapeuticeffectofsubsequentplatinumcontainingchemotherapyinpatientswithrecurrentovariancancerinitiallytreatedwithbevacizumabsgsg018intergroupstudy |